Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivosidenib or enasidenib with azacitidine in newly diagnosed IDH1/IDH2-mutated AML unfit for intensive chemotherapy
NL-OMON60246Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Jan 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ivosidenib, enasidenib and azacitidine in acute myeloid leukemia (AML) (3 arms), sponsored by Celgene Corporation. Primary endpoints: Recommended combination dose, Safety and tolerability and 1 more. Started Jan 2017; status: completed.
02
Drugs
ivosidenibenasidenibazacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NL-OMON60246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60246.